CCRM
Erik K. is an experienced investment professional currently serving as an Investment Manager at CCRM since November 2017, focusing on preclinical-stage companies in cell, gene therapies, and regenerative medicine. Prior roles include Senior Associate, Senior Investment Analyst, and Investment Analyst at Jaqar Corporate Strategy, specializing in M&A advisory and financial modeling. Erik has also held positions as an Investor Relations Analyst at EZTEC, where successful investor relations efforts led to multiple awards, and as a Trading Desk Intern at Macquarie Group, developing hedging strategies for commodities. Earlier experience includes a role as an Investor Relations Intern at Gafisa, supporting investor communications. Erik holds a Master's of Finance from Queen's University and a Bachelor's degree in Economics from USP, with additional CFA Level 1 specialization in Finance.
This person is not in any teams
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.